Top UK director buys: the headline

The Hargreaves Lansdown / Sharecast director dealings round-up dated 28 May 2026 highlighted three of the most notable UK director buys of the week. CVS Group (CVSG) saw group general counsel Scott Morrison purchase 987 shares at 1,269.68p for £12,531.75. Naked Wines (WINE) was listed twice, with director Jack Pailing buying 26,500 shares at 75.00p (£19,875.00) and a further 26,250 shares at 75.00p (£19,687.50), for a combined value of £39,562.50. Baillie Gifford Shin Nippon (BGS) saw director Abigail Rotheroe purchase 7,438 shares at 160.44p, for £11,933.53.

Each transaction tells a slightly different story about UK insider buying — in midcap healthcare, in a turnaround consumer name, and in a Japan smaller-companies Investment trust.

CVS Group: a small but visible CVSG insider buy

CVS Group, the FTSE 250-listed veterinary services Business, has been working through a more cautious share price phase as the UK Competition and Markets Authority continues its market investigation into the Supply of veterinary services for household pets. Against this backdrop, Scott Morrison's £12,531.75 share purchase is a small but visible signal that a senior insider, in this case the group general counsel, has chosen to commit personal Capital at current valuations.

Investors interested in the CVSG investment case typically look at UK and Australian veterinary Demand, clinical labour cost dynamics and the eventual scope of any CMA remedies. The dealing may draw attention, but it should be assessed alongside fundamentals.

Naked Wines: insider purchases at 75.00p

Naked Wines, the AIM-listed online wine retailer, was listed twice in the top director buys section, both at 75.00p. The combined £39,562.50 of director-linked purchases stands out because of the price at which they were executed: 75.00p represents a substantially reset share price compared with the company's Pandemic-era peaks.

Bulls argue that the trades may reflect insider conviction that the company's turnaround is taking hold; bears note that the company is still in transition. The transaction does not necessarily indicate future share price performance.

Baillie Gifford Shin Nippon: an investment trust director buy

Baillie Gifford Shin Nippon plc (BGS), the London-listed investment trust focused on Japanese smaller companies, saw director Abigail Rotheroe purchase 7,438 shares at 160.44p, for £11,933.53. Investment trust director purchases are typically read as a signal of alignment between board members and shareholders.

The BGS dealing is small in absolute terms but sits within a broader debate about Japan smaller-companies exposure and discount-to-NAV dynamics across the UK closed-end fund space.

Why investors monitor director buys

Private investors often pay attention to director purchases because the people transacting have a near-front-row seat to operational performance. They know the order book, the pipeline, the customer base and the trading environment. A director who chooses to put personal capital into the same shares they are paid to manage is, at minimum, signalling that they do not expect a near-term collapse in fundamentals.

However, this signal can be noisy. Directors are sometimes required to maintain a minimum shareholding, and some buys are small relative to a director's overall Wealth. A purchase made by a newly appointed director, for example, can be more about complying with internal shareholding guidelines than a directional view on the share price. Investors may watch director purchases, but they are typically most useful when assessed alongside fundamentals, valuation, guidance and any recent trading updates.

Director dealings explained

Director dealings are share transactions carried out by company directors or persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. Under the UK Market Abuse Regulation (UK MAR), such transactions must be disclosed to the market within three business days of the trade. These filings are published via the London Stock Exchange's Regulatory News Service (RNS) and republished by data providers including Sharecast, Hargreaves Lansdown and Investegate.

For private investors, director dealings have long been one of several signals worth tracking. Academic and broker research suggests that aggregated director buying can, over time, modestly outperform broader benchmarks, although results vary widely by company and by year. Director purchases are often interpreted as a sign of management confidence, while director sales can have many explanations, including tax planning, Diversification, the funding of share option exercises, or simple personal Liquidity needs. None of these transactions, on their own, indicates wrongdoing or future performance, but investors may still watch them closely as one input among many.

Bull case across the buys

Across the three names, bulls might argue that the pattern of insider buying — in different sectors and at different stages of the cycle — reflects a broader view by senior insiders that current valuations offer reasonable entry levels. The CVSG buy looks like a measured response to a regulatory overhang; the Naked Wines buys look like turnaround conviction; and the BGS buy looks like an alignment of trust-board interests with those of shareholders.

From this angle, director purchases are often monitored by the market, particularly when they cluster across multiple unrelated names.

Bear case across the buys

Bears could counter that none of the three buys is particularly large in absolute terms. £12,531.75 at CVS Group, £39,562.50 across two Naked Wines trades and £11,933.53 at BGS together total a modest sum compared with the Market Value of each name. Bears might also note that director purchases can sometimes be motivated by minimum shareholding requirements or by personal circumstances, rather than directional conviction.

From this view, none of the trades alters the underlying debate around the respective business cases or NAV dynamics. The transaction does not necessarily indicate future share price performance.

Key risks across the buys

Each name has its own risk profile. CVS Group faces Regulatory Risk from the CMA inquiry, clinical labour cost Inflation and currency exposure to Australian Earnings. Naked Wines faces subscriber durability risk, Working Capital intensity, FX exposure across the UK, US and Australian markets, and AIM liquidity considerations. BGS faces Japan small-cap Volatility, currency risk, discount risk and broader macroeconomic sensitivity.

Investors building exposure across multiple director buy names should consider these risks at both the individual and portfolio levels.

Balanced conclusion

The top UK director buys of the week — CVS Group, Naked Wines and Baillie Gifford Shin Nippon — together provide a useful snapshot of how UK insiders are engaging with their own shares in mid-2026. Each name brings its own context, from a regulatory overhang to a turnaround story to a Japan smaller-companies investment trust.

Director purchases are often monitored by the market, but they should always be assessed alongside fundamentals. None of these transactions, on their own, indicates future share price performance, but they all add to the broader picture for investors building UK insider buying watchlists.

UK Market Abuse Regulation and PDMR disclosures explained

Under the UK Market Abuse Regulation (UK MAR), persons discharging managerial responsibilities (PDMRs) at issuers admitted to a UK regulated market or multilateral trading Facility must notify both the issuer and the Financial Conduct Authority (FCA) of every transaction conducted on their own account in the shares or Debt instruments of that issuer, or in related financial instruments. Notification must take place within three business days of the transaction. The issuer is, in turn, required to make the information public promptly via a Regulatory Information Service (RIS) such as the London Stock Exchange's RNS service. The same rules apply to persons closely associated with PDMRs, which can include spouses, dependent children, and certain associated legal entities.

The rationale behind UK MAR is to support market integrity. By requiring rapid, public disclosure of insider transactions, the regulation aims to ensure that investors have access to the same information about board-level engagement with their company's shares. There is also a 'closed period' regime, under which PDMRs are typically prohibited from dealing for a 30-day window before the publication of interim or annual financial reports, unless specific exemptions apply. These rules sit alongside broader UK MAR provisions on insider lists, market soundings and the prevention of insider dealing and market manipulation. For investors, the practical takeaway is that director dealings disclosures are not informal updates: they are mandatory, time-bound notifications made under a regulatory framework that takes market abuse seriously.

Director dealings versus other signals UK investors track

Director dealings are best understood as one input within a broader signal set. Other commonly tracked inputs for UK shares include trading updates (which provide direct commentary from management on operational and financial performance), broker consensus forecasts (which aggregate analyst expectations on Revenue, profit and dividends), short interest data (which indicates the scale of bearish positioning), institutional shareholding changes filed via TR-1 notifications, and Macroeconomic Indicators such as consumer confidence, real wages and interest rates.

In this wider context, a single director purchase or sale is unlikely to be the most informative data point for any given investment decision. Trading updates, annual results and broker upgrades or downgrades usually carry more weight, because they reflect operational data and forward-looking estimates. However, director dealings have one specific advantage: they reflect the actions of insiders who are, by definition, in the best position to understand the company's near-term trajectory. That is why investors may watch director purchases and sales alongside other signals, even when they do not, on their own, indicate future share price performance.

What to watch next

For CVS Group investors, the next set of meaningful disclosures will likely include trading updates from the UK and Australian businesses, any communications relating to the Competition and Markets Authority market investigation into UK vet services, and broader peer-group commentary on clinical labour costs. Investors may also watch for further PDMR dealings, particularly any from board members responsible for capital allocation and strategy. CVSG shares should be considered in the context of these inputs rather than any single director transaction.

Five things investors often overlook about director dealings

First, size matters but is not everything. A small absolute purchase by a senior insider can carry more interpretive weight than a much larger trade by a junior PDMR, particularly when it occurs at a fresh share price low or high. Investors who focus solely on cash values can miss this nuance.

Second, the stated reason for a transaction can transform its meaning. A director sale to fund tax on share option exercises is qualitatively different from a discretionary disposal at the same size and price. The issuer's RNS announcement is the authoritative source for the stated reason and should always be consulted directly.

Third, persons closely associated with PDMRs are subject to the same disclosure regime. Dealings by spouses, dependent children and certain associated legal entities are also disclosed. Aggregator headlines sometimes simplify the attribution, so investors who want full clarity should read the underlying RNS.

Fourth, the share price reaction on the day of a disclosure is often noisy. Intraday moves of less than one percent are unlikely to reflect the dealing itself in any meaningful way. Longer-term share price effects, if any, are typically driven by fundamentals.

Fifth, director dealings are one input among many. They are best read alongside trading updates, broker forecasts, Balance Sheet data, valuation metrics and macroeconomic context. The dealing may draw attention, but it should be assessed alongside fundamentals.